×

Rare disease stocks fly on Alexion acquisition

10:07 AM ET Wed, 6 May 2015

Synageva agreed to be acquired by Alexion Pharmaceuticals for about $8.4 billion in cash and stock, reports CNBC's Meg Tirrell.